<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02889965</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL14_0385</org_study_id>
    <nct_id>NCT02889965</nct_id>
  </id_info>
  <brief_title>The French Multiple Sclerosis Registry</brief_title>
  <acronym>OFSEP</acronym>
  <official_title>The French Multiple Sclerosis Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OFSEP is an observational cohort of Multiple Sclerosis (MS) and related disorders set up in&#xD;
      France. It aims to provide a major epidemiological tool on MS for the scientific community in&#xD;
      France and abroad. This tool must help to answer a large number of questions concerning the&#xD;
      causes and mechanisms of MS, the prognostic factors of disease progression, the effectiveness&#xD;
      and safety of therapeutic drugs, the impact of the disease on patients and society, etc.&#xD;
&#xD;
      In December 2015, it has already included more than 54.000 patients. To achieve this goal,&#xD;
      OFSEP's objectives are&#xD;
&#xD;
        -  To maintain and develop the French cohort of patients suffering from MS or related&#xD;
           diseases and syndromes. This means collecting standardized socio-demographic and&#xD;
           clinical data as part of the routine medical follow-up of patients already in the cohort&#xD;
           and recruitment of new patients.&#xD;
&#xD;
        -  To supplement the existing clinical data with standardized and quality biological&#xD;
           samples and MRI scans.&#xD;
&#xD;
        -  To improve the previous data with medical/administrative data from the health insurance&#xD;
           fund databases in particular, in order to get more information on comorbidity, treatment&#xD;
           protocols and the medico-economic aspects of this disease.&#xD;
&#xD;
        -  To use OFSEP infrastructures to facilitate the implementation of specific studies&#xD;
           requiring the collection of additional data or specific patient monitoring processes.&#xD;
&#xD;
        -  To ensure the availability of these data and samples to researchers, health care&#xD;
           authorities and industrial players to enable analysis and thus provide answers to&#xD;
           research questions or public health issues. This availability is only possible after&#xD;
           scientific and regulatory evaluation of the request.&#xD;
&#xD;
        -  To provide regular descriptions of the patient population in the cohort to offer&#xD;
           statistics, targets and up-to-date information on this disease and thus enable a better&#xD;
           approach to the personal, professional and social impacts of the illness, the effects of&#xD;
           basic treatments and the requirements related to the follow-up of this disease in&#xD;
           France.&#xD;
&#xD;
        -  To conduct specific studies on the entire population of patients in the cohort (parent&#xD;
           cohort) or on patient sub-groups with specific characteristics (nested cohorts). Four&#xD;
           nested cohorts have been defined: patients with radiologically isolated syndromes,&#xD;
           patients with clinically isolated syndromes, patients with primary progressive courses&#xD;
           of the disease and patients with neuromyelitis optica (Devic's syndrome) spectrum&#xD;
           disorders.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of cases of MS included</measure>
    <time_frame>6 months up to 8 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of patients</measure>
    <time_frame>6 months up to 8 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>demographic characteristics</measure>
    <time_frame>6 months up to 8 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>geographical distribution</measure>
    <time_frame>6 months up to 8 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>disease characteristics</measure>
    <time_frame>6 months up to 8 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>simple disease-modifying treatment description</measure>
    <time_frame>6 months up to 8 years</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">54000</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Neuromyelitis Optica Spectrum Disorders</condition>
  <arm_group>
    <arm_group_label>Radiologically Isolated Syndromes (RIS)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinically Isolated Syndromes (RIS)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary progressive MS (PPMS)</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All MS and NMOSD patients domiciliated in France&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  RIS&#xD;
&#xD;
          -  CIS&#xD;
&#xD;
          -  MS according to McDonald 2010 criteria&#xD;
&#xD;
          -  NMOSD and others as per NOMADMUS criteria&#xD;
&#xD;
          -  No age limt&#xD;
&#xD;
          -  All clinical courses&#xD;
&#xD;
          -  Domiciliated in France&#xD;
&#xD;
          -  Signed OFSEP informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        NONE&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra VUKUSIC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra VUKUSIC</last_name>
    <phone>33 4 72 35 73 42</phone>
    <email>sandra.vukusic@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>VÃ©ronique MILLOT</last_name>
    <phone>33 4 72 35 73 42</phone>
    <email>veronique.millot@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospices Civils de Lyon / Hopital Neurologique Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 22, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>September 6, 2016</last_update_submitted>
  <last_update_submitted_qc>September 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Pharmacoepidemiology</keyword>
  <keyword>Disease modifying drugs</keyword>
  <keyword>Neuro-myelitis optica</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neuromyelitis Optica</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

